Zennovation in sedation – the next generation of alpha-2 agonists’

The presentation will provide a review of canine sedation, particularly the physiology of alpha-2 receptors and the pharmacology of alpha-2 adrenoreceptor agonists and their reversal. It will also introduce the unique new alpha-2 combination product, Zenalpha, containing the alpha-2 agonist medetomidine and the peripherally selective alpha-2 antagonist vatinoxan. Attendees will learn about the innovative mechanism of action of Zenalpha and how this provides unique benefits, including reduced cardiovascular side effects during sedation.

• The physiology of alpha-2 receptors and that the location of the receptor influences its effect
• The basic pharmacology of alpha-2 agonists and antagonists
• How Zenalpha works, how to use it, what benefits it can bring, to canine patients and the team